7:30 am Registration, Coffee & Networking

8:20 am Chair’s Opening Remarks

8:30 am Experiment with Immune Targeting Therapeutics Agents & Synthetic Mouse Model

The Changing Expectations of Model Requirements

8:55 am Developing Human Target Knock-In Mouse Models for Immuno-Oncology Drug Discovery

Synopsis

  • Lack of animal models for preclinical efficacy evaluation of human therapeutic antibodies for cancer immunotherapies
  • HuGEMM mouse models, created by knocking in chimeric checkpoint targets with human extracellular domains; together with HuCELL syngeneic tumor lines, expressing human TAAs, offer a robust platform for efficacy & safety assessment, as well as MOA of specific human biological therapeutics in vivo

9:20 am Opportunities & Challenges in Utilizing Humanized Mice to Model Human T Cell Responses

  • Mike Brehm Professor , University of Massachusettes

Synopsis

  • Exploring recent advances in humanised models with a natural and translationally relevant tumor microenvironments in enabling the effective preclinical characterization and pharmacodynamic evaluation of IO therapeutics
  • Discussing the remaining challenges and potential for these mice in rational combination design to antitumor responses and minimise tumor escape

9:45 am Addressing the Demand for Clinically Relevant Models in IO Research

  • Rick Huntress Director of Commercial Business Development , The Jackson Laboratory

Synopsis

  • Understand how animal models can provide accurate in vivo conditions to mimic the natural tumour environment
  • Presenting data on how these humanized models in combination with patientderived xenografts can be used to study immune checkpoint blockade
  • Providing valuable insights in predicting both combinatorial therapy efficacy, identifying unmet clinical needs, improving the value of preclinical modeling and ultimately impacting patient outcomes in the clinic

10:10 am Panel Discussion – The Changing Expectations of Model Requirements

  • Davy Ouyang Executive Director , Crown Bioscience
  • Mike Brehm Professor , University of Massachusettes
  • Rick Huntress Director of Commercial Business Development , The Jackson Laboratory

10:30 am Speed Networking

11:00 am Morning Refreshments

Advances in Preclinical and Translational Imaging

11.30 Ultrasound Imaging of Patient-Derived Xenograft to Investigate Intratumoral Heterogeneous Response

  • Demonstrating chicken embryo as a receptive and highly efficient host for patient-derived xenograft modelling, allowing for multiregional “tumor avatar” studies
  • Showcasing how ultrasound imaging can provide rapid, reproducible, and high-resolution quantification of tumor volume, blood flow, and perfusion
  • Functional tumor heterogeneity, in the context of systemic and immune-therapies, exists at the time of nephrectomy and is a phenotype-based readout of genetic tumor heterogeneity

Fred Roberts, Sales Manager, Fujifilm Visual Sonics


11.45 Characterization of Mouse Syngeneic Tumor Models Using Multiplex T Cell Panel

  • Discussing the workflow for establishment of multiplex T cell panel assay validation and image analysis
  • Exploring the spatial infiltration of T cells in tumor microenvironment and its implications on tumor behaviour in syngeneic mouse tumor models
  • Discussing the translational importance of multiplex T cell panel quantitative analysis in decision making for drug candidate selection and patient selection in clinic: a pharmacodynamic case study

Omid Ghasemi, Scientist I, Imaging, Takeda


12.10 Using 3D Imaging & AI to Advance Preclinical Cancer Research

  • The benefits of digitising subcutaneous tumour measurement – greater accuracy, reproducibility and traceability
  • How Fuel3D’s BioVolume solution can power better science and improve the early discovery of biomarkers

Juan Delgado, Lead Data Scientist, Fuel3D


12.25 Using Clearing-Enhanced 3D (Ce3D) to Dissect Tumor Immune Microenvironment in Genetically Egineered Mouse Models

  • Investigating immune cell populations in 3D
  • Combining transcriptomic analysis and Ce3D to study the functions of immune cells in tumor microenvironment
  • Visualizing lung microbiota in lung adenocarcinoma

Chen Zhao, Clinical Fellow, National Institutes of Health


12.50 Q&A Panel - Advances in Preclinical & Translational Imaging

Omid Ghasemi, Scientist I, Imaging, Takeda
Chen Zhao, Clinical Fellow, National Institutes of Health

Advancing Biologic Therapeutics

1:10 pm Lunch

Engineering & Targeting the Microenvironment

2.10 Applications of An In-Vitro Multi-Cell Model of the Tumor Microenvironment

  • Describing the development and validation of a novel multi-cellular 3D in vitro system for pancreatic cancer and non-small cell lung carcinoma
  • Recreating multiple aspects of cancer biology through the combination of microvascular endothelial cells exposed to tumor hemodynamics, stromal cells and tumor
  • Highlighting its applications for the development of effective anticancer agents and implications for patient avatars

Daniel Gioeli, Associate Professor,  University of Virginia


2.35 Attention to Metastasis: Understanding Importance of Tumor Microenvironment In Immunotherapy Development

  • Significance of preclinical metastasis models
  • Triple-negative breast cancer primary tumor and bone metastasis models in humanized mice and effects of immunotherapy
  • Estrogen receptor positive breast cancer models: importance to follow adverse reactions of estrogen and immunotherapies

Jenni Bernoulli, COO, Pharmatest Services


2.50 Targeting Immunosuppression in the Tumor Microenvironment – Modelling Tumor-Immune Interactions In Vitro

  • Performing compound profiling of targeted IO combination therapies in 3D models to aid in vitro in vivo translation
  • Analyzing immune suppressive features of co-culture
  • Highlighting the applications of co-culture to profiling targeted therapies using multiple readouts

Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis


3.15 Q&A Panel – Engineering & Targeting The Microenvironment

Silvia Goldoni, Investigator & Head of Oncology Lab, Novartis
Daniel Gioeli, Associate Professor,  University of Virginia

Novel Models for Novel Targets

3:35 pm Afternoon Refreshments

Modelling Cancer Drug Resistance

4:05 pm Syngeneic Models of Breast and Ovarian Cancers: Effects of Immune Modulatory Agents in Classically “Cold” Tumors

Synopsis

  • Utilization of murine breast cancer models in preclinical immuno-oncology pharmacology
  • Pros and cons of the 4t1 mammary cancer model
  • Characteristics of alternative syngeneic breast models
  • Responses of a new model to checkpoint inhibition and t cell costimulation

4:30 pm Translational Strategies to Overcome Primary, Acquired & Adaptive Resistance

  • Corinne Reimer Associate Director, In Vivo Pharmacology, AstraZeneca

Synopsis

  • Understanding the potential of humanized and syngeneic models in recapitulating the tumor microenvironment
  • Showcasing the generation humanized systems to validate targets in the myeloid compartment to overcome resistance
  • Exploring approaches to analyze MDSCs in humanized PDx models

4:55 pm A Clinically-Predictive Ex-Vivo Tumor Modeling Platform for Drug Discovery and Development

  • Stefan Jellbauer Technical Liaison for Translational Applications , Mitra Biotech

Synopsis

  • Exploring the development and clinically validation of a fully human ex-vivo tumor platform technology (CANscript™)
  • CANscript ™ uses patient material (tumor, autologous ligands and PBMCs) to explore the mechanism of action and predict efficacy for clinically-directed compounds in a modality agnostic way using phenotypic readouts
  • Showcasing how we use CANscript to measure the effect of checkpoint inhibitor monotherapy or combination to deepen our understanding of response and resistance

5:20 pm Q&A – Modelling Cancer Drug Resistance

  • Corinne Reimer Associate Director, In Vivo Pharmacology, AstraZeneca
  • Stefan Jellbauer Technical Liaison for Translational Applications , Mitra Biotech

5:50 pm Close of Conference Day One

6:00 pm Evening Drinks Reception & Poster Session Hosted by Crown Biosciences